325 related articles for article (PubMed ID: 27941540)
21. P504S/alpha-methylacyl-CoA racemase: a useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy.
Jiang Z; Wu CL; Woda BA; Dresser K; Xu J; Fanger GR; Yang XJ
Am J Surg Pathol; 2002 Sep; 26(9):1169-74. PubMed ID: 12218573
[TBL] [Abstract][Full Text] [Related]
22. Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion.
Herawi M; Parwani AV; Irie J; Epstein JI
Am J Surg Pathol; 2005 Jul; 29(7):874-80. PubMed ID: 15958851
[TBL] [Abstract][Full Text] [Related]
23. The diagnostic use of ERG in resolving an "atypical glands suspicious for cancer" diagnosis in prostate biopsies beyond that provided by basal cell and α-methylacyl-CoA-racemase markers.
Shah RB; Tadros Y; Brummell B; Zhou M
Hum Pathol; 2013 May; 44(5):786-94. PubMed ID: 23158212
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
25. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
26. SPINK1 protein expression and prostate cancer progression.
Flavin R; Pettersson A; Hendrickson WK; Fiorentino M; Finn S; Kunz L; Judson GL; Lis R; Bailey D; Fiore C; Nuttall E; Martin NE; Stack E; Penney KL; Rider JR; Sinnott J; Sweeney C; Sesso HD; Fall K; Giovannucci E; Kantoff P; Stampfer M; Loda M; Mucci LA
Clin Cancer Res; 2014 Sep; 20(18):4904-11. PubMed ID: 24687926
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical pitfalls in prostate pathology.
Brimo F; Epstein JI
Hum Pathol; 2012 Mar; 43(3):313-24. PubMed ID: 22325142
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.
Jiang Z; Woda BA
Adv Anat Pathol; 2004 Nov; 11(6):316-21. PubMed ID: 15505533
[TBL] [Abstract][Full Text] [Related]
30. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literature.
Varma M; Jasani B
Histopathology; 2005 Jul; 47(1):1-16. PubMed ID: 15982318
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Value of Twist-1, E-cadherin and EZH2 in Prostate Cancer: An Immunohistochemical Study.
Abdelrahman AE; Arafa SA; Ahmed RA
Turk Patoloji Derg; 2017; 1(1):198-210. PubMed ID: 28832071
[TBL] [Abstract][Full Text] [Related]
33. [Role of tissue markers on diagnosis, prognosis and monitoring of prostate cancer].
Mora MJ
Arch Esp Urol; 2015 Apr; 68(3):250-66. PubMed ID: 25948798
[TBL] [Abstract][Full Text] [Related]
34. Typing the atypical: Diagnostic issues and predictive markers in suspicious prostate lesions.
Sanguedolce F; Cormio A; Musci G; Troiano F; Carrieri G; Bufo P; Cormio L
Crit Rev Clin Lab Sci; 2017 Aug; 54(5):309-325. PubMed ID: 28828885
[TBL] [Abstract][Full Text] [Related]
35. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301
[TBL] [Abstract][Full Text] [Related]
36. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
37. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
38. [New markers in prostate biopsies].
Molinié V; Baumert H
Actas Urol Esp; 2007 Oct; 31(9):1009-24. PubMed ID: 18257370
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
40. [Usefulness of bcl-2 expression as a new basal cell marker in prostatic pathology].
Ramos Soler D; Mayordomo Aranda E; Calatayud Blas A; Rubio Briones J; Solsona Narbón E; Llombart Bosch A
Actas Urol Esp; 2006 Apr; 30(4):345-52. PubMed ID: 16838605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
